JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
Scope & Guideline
Pioneering Discoveries in Drug Behavior
Introduction
Aims and Scopes
- Population Pharmacokinetics and Pharmacodynamics:
The journal emphasizes studies that utilize population pharmacokinetic and pharmacodynamic models to analyze drug behavior in diverse patient populations. This area is crucial for optimizing dosing regimens and understanding variability in drug responses. - Quantitative Systems Pharmacology (QSP):
QSP is a core focus, integrating biological systems modeling with pharmacokinetic and pharmacodynamic principles. This approach aids in predicting drug effects and interactions within complex biological systems, facilitating better drug development strategies. - Mechanistic and Semi-Mechanistic Modeling:
Research that develops mechanistic or semi-mechanistic models to describe drug action and interactions at various biological levels is prevalent. These models help elucidate the underlying biological processes affecting drug behavior. - Innovative Computational Techniques:
The journal showcases the application of advanced computational techniques, including machine learning and artificial intelligence, to pharmacokinetic and pharmacodynamic modeling, aiming to improve predictive accuracy and model efficiency. - Clinical Applications and Translational Research:
There is a strong emphasis on studies that bridge the gap between theoretical modeling and clinical application, particularly in areas such as oncology, rare diseases, and chronic conditions, enhancing the relevance of pharmacometric research to real-world clinical scenarios.
Trending and Emerging
- Integration of Machine Learning in Pharmacometrics:
There is a growing trend in utilizing machine learning techniques to enhance pharmacometric modeling. This includes applications in model selection, optimization, and predictive analytics, which are increasingly recognized for their potential to improve the robustness and efficiency of pharmacokinetic/pharmacodynamic analyses. - Focus on Rare Diseases and Pediatric Populations:
Research addressing pharmacokinetics and pharmacodynamics in rare diseases and pediatric populations is gaining momentum. This reflects a broader recognition of the need for tailored therapeutic strategies in these vulnerable groups. - Virtual Patient Models and Simulations:
The use of virtual patient models and simulations to predict drug responses and optimize treatment regimens is on the rise. These models allow for the exploration of various dosing scenarios and patient characteristics, enhancing translational research efforts. - Mechanistic Insights into Drug Action:
There is an increasing emphasis on studies that provide mechanistic insights into drug action and interactions, particularly through the development of semi-mechanistic and mechanistic models. This trend supports a deeper understanding of how drugs exert their effects at the biological level. - Emphasis on Quantitative Systems Pharmacology (QSP):
QSP is becoming a dominant theme, with a focus on integrating biological data with pharmacometric models to enhance the predictive capabilities of drug development processes. This approach is critical for improving the translation of preclinical findings to clinical outcomes.
Declining or Waning
- Traditional Compartmental Models:
There has been a noticeable decrease in the publication of studies exclusively relying on traditional compartmental models. As more sophisticated modeling approaches, such as physiologically-based pharmacokinetic (PBPK) models, gain traction, the relevance of simpler compartmental methods appears to be waning. - Basic Pharmacokinetic Studies:
Research focused solely on basic pharmacokinetic parameters without integrating pharmacodynamic aspects or clinical implications has decreased. The journal is increasingly favoring studies that combine pharmacokinetics with pharmacodynamics to provide a more comprehensive analysis. - Single-Agent Drug Studies:
The focus on studies examining the pharmacokinetics and pharmacodynamics of single-agent drugs is declining, as there is a growing interest in combination therapies and their complex interactions, particularly in oncology and chronic disease treatment. - Static Modeling Approaches:
Static models that do not account for variability or dynamic changes in drug effects over time are being replaced by more dynamic and flexible modeling approaches. This trend indicates a shift towards methods that better capture the complexities of drug action in real-world scenarios.
Similar Journals
Journal of Pharmacological Sciences
Bridging knowledge and practice in pharmacological sciences.Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
Transforming drug therapy with scholarly excellence.INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany, is a vital scholarly platform dedicated to advancing the field of pharmacology through rigorous research and innovative therapeutic strategies. Established in 1994, this journal has maintained its relevance in the evolving landscape of clinical pharmacology, achieving a Q3 rank in both general and medical pharmacology categories as of 2023. With an ISSN of 0946-1965, it is positioned as an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding of drug therapy and pharmacological applications. Though it currently does not offer open access, its comprehensive scope covers a wide array of topics within pharmacology, promising to contribute significantly to scientific discussions and knowledge dissemination from 1994 to 2024. Whether you are looking for the latest studies or historical insights, the journal remains a fixture for anyone invested in the pharmacological sciences.
CURRENT OPINION IN PHARMACOLOGY
Illuminating Trends in Pharmacology and BeyondCurrent Opinion in Pharmacology, an esteemed journal published by Elsevier Science Ltd, encompasses the vital field of pharmacology and drug discovery. With a solid impact factor and recognized as a Q1 journal in both Drug Discovery and Pharmacology categories for 2023, it serves as a premier platform for researchers and professionals to share innovative insights, discuss emerging trends, and explore the complexities of drug development and therapeutic applications. Established in 2001 and running through 2024, this journal provides a critical overview of advances in the field, aiming to inform and inspire the next generation of pharmacological research. Despite lacking Open Access options, it maintains a high standard of scholarly excellence, ensuring that the content remains impactful and relevant to its readers. The journal is based in the Netherlands, representing a key contributor to the academic landscape in pharmacology.
Drug Design Development and Therapy
Pioneering the Future of Drug Design and Patient CareDrug Design Development and Therapy is a premier open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of drug discovery, pharmaceutical science, and pharmacology. With an impressive Q1 ranking in its categories as of 2023, this journal is recognized for its significant contributions to the understanding of drug design and therapeutic innovations, making it an invaluable resource for researchers, professionals, and students alike. Established in 2007 and committed to open-access since 2008, the journal provides an inclusive platform for disseminating high-quality research from around the globe. With a robust impact factor and remarkable Scopus rankings, including a 24th place in Pharmaceutical Science and a 48th place in Pharmacology, it reflects a strong percentile performance, ensuring that published articles reach and impact a wide audience. By fostering the exchange of cutting-edge information on drug development and delivery systems, Drug Design Development and Therapy continues to play a crucial role in the ongoing battle against disease, promoting innovative approaches to therapeutic solutions and enhancing patient care.
ACTA PHARMACOLOGICA SINICA
Unveiling Breakthroughs in Medicine and PharmacologyACTA PHARMACOLOGICA SINICA is a premier journal in the field of pharmacology, published by the esteemed Nature Publishing Group. With a strong history since its inception in 1980, this journal is recognized for its impactful contributions to the fields of medicine and pharmacology, consistently securing a Q1 ranking in multiple relevant categories, including Pharmacology (Medical). Drawing on a robust international readership, it ranks impressively at #8 out of 272 in the specialty of Medical Pharmacology, placing it in the top 97th percentile according to Scopus data. Although currently not an open-access publication, ACTA PHARMACOLOGICA SINICA remains a vital resource for researchers, professionals, and students seeking to advance their understanding of pharmacological sciences. Its commitment to disseminating high-quality research underscores its significance in fostering innovation and exploration in the medical landscape.
BRITISH JOURNAL OF PHARMACOLOGY
Pioneering insights into drug mechanisms and therapeutic innovations.British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.
BMC Pharmacology & Toxicology
Unveiling the complexities of drug action and safety.Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.
DARU-Journal of Pharmaceutical Sciences
Fostering open access to transformative pharmaceutical research.DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.
ANTI-CANCER DRUGS
Pioneering Discoveries in Oncology PharmacologyANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.
European Journal of Pharmacology
Shaping the future of pharmacology through impactful scholarship.The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.